SRL Ranbaxy to Market DiaGenic's Breast Cancer Dx in India

May 23, 2008

NEW YORK (GenomeWeb News) – Norwegian diagnostics developer DiaGenic said today that it has signed up SRL Ranbaxy to market its genomic breast cancer test in India.

SRL Ranbaxy is a clinical reference pathology lab network with 40 labs and around 750 collection centers in India.

DiaGenic said it conducted a study of its blood-based gene expression test in India that showed it was not affected by variations in ethnicity or by the menopausal state of the patient.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Main menu